Crinetics Pharmaceuticals, Inc.

CRNX

NASDAQ

Healthcare

Biotechnology

San Diego, CA, US437 employeescrinetics.com

$37.10

+0.54(1.46%)

Mkt Cap $3.9B

$25.56

$56.43

52-Week Range

At a Glance

AI-generated

Revenue breakdown: License And Service (44.8%), Product (33.2%), License (22%).

8-K

Crinetics Pharmaceuticals, Inc. disclosed that Jeff Knight resigned as Chief Development and Operating Officer, effective on or about April 10, 2026, after notifying the company on March 17, 2026. The resignation is to pursue another opportunity with no disagreement on operations, policies, or practices, and his responsibilities will be reassigned to the executive leadership team.

$3.9B

Market Cap

$6M

Revenue

-$518M

Net Income

Employees437

Fundamentals

How The Business Makes Money

Revenue by Segment

License And Service44.8%($15M)

Product33.2%($11M)

License22%($7M)

Activity

What Changed Recently

Management Change

Mar 22, 2026

Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 17,

Management Change

Jan 25, 2026

Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 20

Financial Results

Feb 25, 2026

Results of Operations and Financial Condition. On February 26, 2026 , Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) issued a press release repo

Financial Results

Jan 12, 2026

Results of Operations and Financial Condition. On January 13, 2026, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) reiterated certain previously

Auditor Change

Mar 2, 2026

Changes in Registrant's Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On February 27, 2026, the Audit Committee (the "Au

Peer Companies

Company	Price	Change	Market Cap	P/E
KYMRKymera Therapeutics, Inc.	$85.33	+0.47%	$7.0B	-20.9
PRAXPraxis Precision Medicine...	$310.78	-2.66%	$6.6B	-21.8
IMVTImmunovant, Inc.	$24.67	-1.70%	$5.0B	-9.5
AKROAKRO	$54.65	+0.00%	$4.5B	—
XENEXenon Pharmaceuticals Inc...	$56.70	+0.02%	$4.5B	-12.5
VKTXViking Therapeutics, Inc.	$34.87	+5.79%	$4.0B	-10.3
NAMSNewAmsterdam Pharma Compa...	$33.02	+0.64%	$3.8B	-16.8
ACADACADIA Pharmaceuticals In...	$22.18	-0.65%	$3.8B	9.1

Analyst View

Company Profile

CIK0001658247

ISINUS22663K1079

CUSIP22663K107

Phone858 450 6464

AddressBuilding No. 2, San Diego, CA, 92121, US

SEC EDGAR